Vanguard Group
ODT

Vanguard Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Vanguard Group’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-964,818
Closed -$1.3M – 4686
2021
Q4 		$1.3M Buy
964,818
+2,619
+0.3% +$6.19K ﹤0.01% 4185
2021
Q3 		$2.8M Sell
962,199
-6,488
-0.7% -$21.6K ﹤0.01% 3944
2021
Q2 		$3.38M Buy
968,687
+10,100
+1% +$34.7K ﹤0.01% 3784
2021
Q1 		$3.28M Sell
958,587
-10,120
-1% -$191K ﹤0.01% 3725
2020
Q4 		$18.6M Buy
968,707
+198,536
+26% +$3.06M ﹤0.01% 2671
2020
Q3 		$10.3M Buy
770,171
+88,100
+13% +$2.5M ﹤0.01% 2769
2020
Q2 		$28.9M Buy
682,071
+15,732
+2% +$509K ﹤0.01% 2255
2020
Q1 		$18.4M Sell
666,339
-8,755
-1% -$255K ﹤0.01% 2331
2019
Q4 		$21.9M Buy
675,094
+2,419
+0.4% +$75K ﹤0.01% 2493
2019
Q3 		$17.5M Buy
672,675
+225,264
+50% +$7.54M ﹤0.01% 2553
2019
Q2 		$16.4M Buy
447,411
+85,133
+23% +$2.04M ﹤0.01% 2610
2019
Q1 		$8.01M Buy
362,278
+144,148
+66% +$2.52M ﹤0.01% 2940
2018
Q4 		$3.07M Sell
218,130
-98,603
-31% -$1.54M ﹤0.01% 3252
2018
Q3 		$6.15M Buy
316,733
+49,528
+19% +$1.01M ﹤0.01% 3153
2018
Q2 		$5.9M Buy
267,205
+20,008
+8% +$466K ﹤0.01% 3151
2018
Q1 		$5.24M Buy
247,197
+186,767
+309% +$4.4M ﹤0.01% 3134
2017
Q4 		$1.51M Buy
+60,430
New +$1.43M ﹤0.01% 3506

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Vanguard Group's ODT Position: Q1 2022 in Review

Vanguard Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 964,818 shares — an estimated $1.3M sold.

Vanguard Group first reported a position in ODT in Q4 2017 and held it in 17 quarters. The position peaked at $28.9M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Vanguard Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Vanguard Group sold 964,818 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.3M.
  • Vanguard Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Vanguard Group's Odonate Therapeutics, Inc. Common Stock position peaked at $28.9M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Vanguard Group's 13F filing for Q1 2022, filed 13 May 2022.